企業主催の治験に以前参加し、治験治療を受けている固形腫瘍患者を対象としたオナルツズマブの延長試験

基本情報

NCT ID

NCT02488330

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

12

治験依頼者名

Hoffmann-La Roche

概要

This extension study will provide continued onartuzumab and/or parent trial (P-trial) designated control treatments to participants with cancer who were previously enrolled in a company-sponsored onartuzumab P-trial and who derived benefit, as assessed by the responsible investigator, from the therapy administered in the P-trial. The study will also collect safety data with regard to administration of continued onartuzumab therapy.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)